259 related articles for article (PubMed ID: 36252265)
1. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
3. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
[TBL] [Abstract][Full Text] [Related]
6. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
7. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
Saha C; Harrison C
Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
[TBL] [Abstract][Full Text] [Related]
8. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian JJ; Vannucchi AM; Verstovsek S; Colak G; Dey D; Harrison C
Blood Adv; 2023 Sep; 7(18):5421-5432. PubMed ID: 37530627
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
10. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
Tremblay D; Mascarenhas J
Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
[TBL] [Abstract][Full Text] [Related]
12. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract][Full Text] [Related]
14. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
15. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Mascarenhas J; Harrison C; Schuler TA; Liassou D; Garretson M; Miller TA; Mahadevan S; McBride A; Tang D; DeGutis IS; Abraham P; Kish J; Feinberg BA; Gerds AT
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):122-132. PubMed ID: 37839939
[TBL] [Abstract][Full Text] [Related]
16. The safety of JAK kinase inhibitors for the treatment of myelofibrosis.
Coltro G; Vannucchi AM
Expert Opin Drug Saf; 2021 Feb; 20(2):139-154. PubMed ID: 33327810
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
18. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract][Full Text] [Related]
19. Fedratinib in myelofibrosis.
Mullally A; Hood J; Harrison C; Mesa R
Blood Adv; 2020 Apr; 4(8):1792-1800. PubMed ID: 32343799
[TBL] [Abstract][Full Text] [Related]
20. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
